2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135245
    Ezetimibe hydroxy glucuronide 536709-33-8 98%
    Ezetimibe hydroxy glucuronide (SCH 488128) is a trace metabolite detected in dog and human plasma samples after oral administration of Ezetimibe (HY-17376).
    Ezetimibe hydroxy glucuronide
  • HY-13524A
    AG-1478 hydrochloride 170449-18-0 98%
    AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. AG-1478 hydrochloride has antiviral effects against HCV and encephalomyocarditis virus (EMCV).
    AG-1478 hydrochloride
  • HY-135328
    Norverapamil 67018-85-3 98%
    Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.
    Norverapamil
  • HY-135358
    (Rac)-5-Keto Fluvastatin 1160169-39-0 98%
    (Rac)-5-Keto Fluvastatin (3-Hydroxy-5-Keto Fluvastatin) is an impurity of Fluvastatin (XU 62320). Fluvastatin is a HMG-CoA reductase inhibitor with an IC50 of 8 nM.
    (Rac)-5-Keto Fluvastatin
  • HY-135379
    Atorvastatin acetonide 581772-29-4 98%
    Atorvastatin acetonide is an impurity of Atorvastatin, and extracted from patent WO2011131605A1, Compound 4. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.
    Atorvastatin acetonide
  • HY-135381
    3-Oxo Atorvastatin 887196-30-7 98%
    3-Oxo Atorvastatin is an impurity of 3-Oxo Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.
    3-Oxo Atorvastatin
  • HY-135388
    ent-Ezetimibe 1376614-99-1 98%
    ent-Ezetimibe (ent-SCH 58235) is the RRS-enantiomer of Ezetimibe. Ezetimibe is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    ent-Ezetimibe
  • HY-135402
    2'-Ethyl Simvastatin 79902-42-4 98%
    2'-Ethyl Simvastatin (compound 6) is a Mevinolin analog, with HMG-CoA reductase inhibition.
    2'-Ethyl Simvastatin
  • HY-135404
    Anhydrosimvastatin 210980-68-0 98%
    Anhydrosimvastatin (Impurity C) is an impurity of Simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase.
    Anhydrosimvastatin
  • HY-135405
    4-Acetylsimvastatin 145576-25-6 98%
    4-Acetylsimvastatin is an acetylated simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    4-Acetylsimvastatin
  • HY-135406
    (3R,5R)-Rosuvastatin Lactone 1422954-11-7 98%
    (3R,5R)-Rosuvastatin Lactone is an isomer of Rosuvastatin Lactone.
    (3R,5R)-Rosuvastatin Lactone
  • HY-135408
    Trimetazidine-N-oxide 1644530-89-1 98%
    Trimetazidine-N-oxide is the major active metabolite of Trimetazidine. Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM. Trimetazidine is an effective antianginal agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties.
    Trimetazidine-N-oxide
  • HY-135446
    BQ-610 141595-53-1 98%
    BQ-610 is a selective antagonist of the endothelin A receptor (ETA receptor). BQ-610 specifically blocks the ETA receptor, competitively inhibiting the binding of endothelin-1 (ET-1) (a vasoconstrictive peptide) to the receptor, thereby blocking the effects of ET-1 such as vascular smooth muscle contraction, cell mitosis, and inhibition of hormone secretion. BQ-610 significantly alleviates cerebral vasospasm in rabbits. BQ-610 blocks the bronchial epithelial and pulmonary vascular cell proliferation caused by cigarette smoke in rat models. BQ-610 can delay the natural luteal regression in the cow's uterus. BQ-610 can be used for research on vasospasm, abnormal cell proliferation, and reproductive endocrine disorders.
    BQ-610
  • HY-135501
    Bamifylline 2016-63-9 98%
    Bamifylline is a drug in the chemical class of xanthine that acts as a selective adenosine A1 receptor antagonist.
    Bamifylline
  • HY-135541
    Darexaban maleate 365462-24-4 98%
    Darexaban maleate (YM150 maleate) is a direct factor Xa inhibitor with activity in preventing venous thromboembolism. The major metabolite of Darexaban maleate in humans is Darexaban glucitol, which acts pharmacologically. The glucitolation reaction of Darexaban maleate is mainly catalyzed by UGT1A9 and UGT1A10 in the human liver and intestine. The K(m) value of Darexaban maleate glucitolation in the liver is greater than 250 μM, while in the intestine it exhibits substrate inhibition kinetics with a K(m) value of 27.3 μM. The unbound K(m) value of Darexaban maleate is significantly reduced by the influence of fatty acid-free bovine serum albumin in both HLM and UGT1A9.
    Darexaban maleate
  • HY-135562
    Ascofuranone 38462-04-3 98%
    Ascofuranone, a prenylphenol antibiotic, is a potent and selective trypanosome alternative oxidase (TAO) inhibitor. Ascofuranone has inhibitory activity against human dihydroorotate dehydrogenase (DHODH). Ascofuranone has diverse physiological activities, including antibiotic, hypolipidemic, anti-inflammatory, and anti-cancer.
    Ascofuranone
  • HY-135571
    VBIT-3 2088463-66-3 98%
    VBIT-3 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 31.3 μM. VBIT-3, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases.
    VBIT-3
  • HY-13559A
    Atiprimod dimaleate 183063-72-1 98%
    Atiprimod (Azaspirane) (dimaleate) is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML).
    Atiprimod dimaleate
  • HY-135601
    Cinacalcet metabolite M4 104774-87-0 98%
    Cinacalcet metabolite M4 is a metabolite of Cinacalcet. Cinacalcet is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease.
    Cinacalcet metabolite M4
  • HY-135773
    CRTh2 antagonist 3 312928-72-6 98%
    CRTh2 antagonist 3 is a potent chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist. CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an EC50 of 2 μM and a Kd of 8.4 μM. CRTh2 antagonist 3 has the potential for cardiovascular inflammation.
    CRTh2 antagonist 3
Cat. No. Product Name / Synonyms Application Reactivity